


# NEWSLETTER #86

July/August 2023


## ASCO poster presentations

Laurien Zeverijn and Birgit Geurts represented DRUP during the ASCO.



Laurien presented the poster entitled “*Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with Cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and*

*Australian MoST trials*“. Birgit presented the poster entitled “*Efficacy and predictors of response of nivolumab in treatment-refractory MSI solid tumors: results of a tumor-agnostic DRUP cohort*“.



## Scientific output

We are pleased to announce that the article entitled “*Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with Cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials*” by Laurien Zeverijn

*et al.* has been accepted for publication in *International Journal of Cancer*. Click [here](#) to view this article.

## Stelvio

Several members of the DRUP study team will participate in the annual sports event of the Stelvio for Life on 2<sup>nd</sup> of September, 2023. During this event the DRUP-team will climb the Stelvio pass in Italy to raise money for cancer research such as the DRUP study. Every team member will climb 1.533 metres either by bike or by foot and are asked to raise €1,- per altitude metre. Would you like to support this great achievement and thereby support cancer research? Click [here](#) to contribute to the DRUP-team.

## Pre-treatment biopsies

Unfortunately, we notice a relatively high percentage of pre-treatment biopsies which could not successfully be sequenced, mainly due to low tumor cell percentage in the biopsies. To increase our success rate we would like to ask your attention for the following:

- Please always send the **first** taken biopsy for analysis to HMF
- Please make clear to the person who takes the biopsies (i.e. radiologist) that it is taken for **research purposes**

We hope that creating more awareness will increase the success rate of sequencing. Thank you all for helping us towards a higher success rate!

**Digital submission form**

From on August 1<sup>st</sup>, 2023 we will process submissions of new patients for both the DRUP and the DAP study via the digital form. This digital form should be sent via secured e-mail to the study team. As discussed in the previous newsletter, we aim to collect information for submissions in a more efficient way for all parties. The form with an explanation will be sent to the sites next week.

**DRUP study update**

To date, 2633 cases have been submitted to the DRUP study, of which 1458 (55%) have started a treatment (Table 2).

**DAP study update**

To date, 259 cases have been submitted to DAP, of which 218 (84%) have started with one of the 7 treatments (Table 3). The first cohort of DAP is now closed, and data of Cemiplimab in advanced cutaneous squamous cell carcinoma is now being analysed.



The study team wishes you a fantastic summer! The next newsletter will be issued in September.

Sponsor Study team	
Principal Investigators DRUP	Emile Voest (NKI-AVL), Henk Verheul (Erasmus MC), Hans Gelderblom (LUMC)
Principal Investigators DAP	Emile Voest (NKI-AVL), Haiko Bloemendal (Radboud UMC), Egbert Smit (LUMC)
Study Coordinators	Laurien Zeverijn, Birgit Geurts, Ilse Spiekman, Karlijn Verkerk, Georgy Gomon, Soemeya Haj Mohammad
Clinical Project Managers	Femke Verwer, Emilie van der Sande
Clinical Trial Assistant	Marion Bleijendaal
<b>Contact:</b>	
DRUP	<a href="mailto:DRUP@nki.nl">DRUP@nki.nl</a>
DAP	<a href="mailto:drugaccess@nki.nl">drugaccess@nki.nl</a>

Calendar	
September 2, 2023	Stelvio for Life (Italy)
September 17 – 19, 2023	NPCM symposium (Oslo)
September 20, 2023	PRIME-ROSE kick-off meeting, (Oslo)
October 20 – 24, 2023	ESMO congress (Madrid)

Publications	
Zeveerijn <i>et al.</i> <i>International Journal of Cancer</i>	Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with Cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.

Table 1: List of pharmaceutical companies & study drugs. Confidential, list might be subjected to changes.																			
DRUP	DRUG Access																		
<p><b>Currently available</b></p> <table border="0"> <tr> <td><u>Amgen</u> Panitumumab</td> <td><u>Eisai</u> Lenvatinib</td> <td><u>MSD</u> Pembrolizumab</td> <td><u>Roche</u> Erlotinib Trastuzumab+ Pertuzumab</td> </tr> <tr> <td><u>BMS</u> Nivolumab Ipilimumab</td> <td><u>AstraZeneca</u> Olaparib Durvalumab</td> <td><u>Lilly</u> Abemaciclib Selpercatinib</td> <td>Vemurafenib+ Cobimetinib Vismodegib</td> </tr> <tr> <td><u>Novartis</u> Dabrafenib Nilotinib Trametinib Alpelisib</td> <td><u>Pfizer</u> Axitinib Crizotinib Sunitinib Talazoparib Dacomitinib Lorlatinib</td> <td><u>Janssen</u> Erdafitinib</td> <td>Atezolizumab+ bevacizumab Alectinib Entrectinib</td> </tr> </table>	<u>Amgen</u> Panitumumab	<u>Eisai</u> Lenvatinib	<u>MSD</u> Pembrolizumab	<u>Roche</u> Erlotinib Trastuzumab+ Pertuzumab	<u>BMS</u> Nivolumab Ipilimumab	<u>AstraZeneca</u> Olaparib Durvalumab	<u>Lilly</u> Abemaciclib Selpercatinib	Vemurafenib+ Cobimetinib Vismodegib	<u>Novartis</u> Dabrafenib Nilotinib Trametinib Alpelisib	<u>Pfizer</u> Axitinib Crizotinib Sunitinib Talazoparib Dacomitinib Lorlatinib	<u>Janssen</u> Erdafitinib	Atezolizumab+ bevacizumab Alectinib Entrectinib	<p><b>Currently available</b></p> <table border="0"> <tr> <td><u>Sanofi</u> Cemiplimab</td> <td><u>Roche</u> Entrectinib</td> </tr> <tr> <td><u>Bayer</u> Larotrectinib</td> <td><u>Lilly</u> Selpercatinib</td> </tr> <tr> <td><u>Merck</u> Tepotinib</td> <td><u>Janssen</u> Amivantamab</td> </tr> </table>	<u>Sanofi</u> Cemiplimab	<u>Roche</u> Entrectinib	<u>Bayer</u> Larotrectinib	<u>Lilly</u> Selpercatinib	<u>Merck</u> Tepotinib	<u>Janssen</u> Amivantamab
<u>Amgen</u> Panitumumab	<u>Eisai</u> Lenvatinib	<u>MSD</u> Pembrolizumab	<u>Roche</u> Erlotinib Trastuzumab+ Pertuzumab																
<u>BMS</u> Nivolumab Ipilimumab	<u>AstraZeneca</u> Olaparib Durvalumab	<u>Lilly</u> Abemaciclib Selpercatinib	Vemurafenib+ Cobimetinib Vismodegib																
<u>Novartis</u> Dabrafenib Nilotinib Trametinib Alpelisib	<u>Pfizer</u> Axitinib Crizotinib Sunitinib Talazoparib Dacomitinib Lorlatinib	<u>Janssen</u> Erdafitinib	Atezolizumab+ bevacizumab Alectinib Entrectinib																
<u>Sanofi</u> Cemiplimab	<u>Roche</u> Entrectinib																		
<u>Bayer</u> Larotrectinib	<u>Lilly</u> Selpercatinib																		
<u>Merck</u> Tepotinib	<u>Janssen</u> Amivantamab																		
<p><b>Committed</b></p> <table border="0"> <tr> <td><u>GSK</u> Niraparib</td> <td><u>Merck</u> Tepotinib</td> </tr> </table>	<u>GSK</u> Niraparib	<u>Merck</u> Tepotinib																	
<u>GSK</u> Niraparib	<u>Merck</u> Tepotinib																		

**Table 2: Submission and accrual overview**July 1<sup>st</sup>, 2023**Table 3: Submission and accrual overview**July 1<sup>st</sup>, 2023**Table 4: European collaboration**

Country	Registration nr	Trial name	Status
The Netherlands	NCT02925234	DRUP	Opened for inclusion since Q3 2016
Denmark	NCT04341181	ProTarget	Opened for inclusion since Q3 2020
Sweden	NCT04185831	MEGALIT	Opened for inclusion since Q4 2020
Norway	NCT04817956	IMPRESS	Opened for inclusion since Q2 2021
Finland	NCT05159245	FINPROVE	Opened for inclusion since Q1 2022
France	NCT02029001	MOST Plus	Opened for inclusion since 2014
United Kingdom	NCT05722886	DETERMINE	Opened for inclusion since Q2 2023
Portugal		POP	Negotiations with pharmaceutical companies and funders
Germany			In progress